Business Insider

Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

SEATTLE, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at the University of ...
Business Insider

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date. Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor ...